IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company's Compensation Committee of the Board of Directors (the "Compensation Committee") approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units ("RSUs") under AEON's 2025 Employment Inducement Incentive Award Plan (the "Induce

IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that on March 31, 2026, it received a notice (the "Notice") from NYSE American LLC ("NYSE American") indicating that, following its year-end financial results, the Company is not in compliance with an additional continued listing standard set forth in the NYSE American Company Guide (the "Company Guide"). As previously disclosed, on February 3, 2025, the Company received a notice (the "Original Notice") that it

– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –  – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (

FDA provided constructive feedback on Company's analytical similarity strategy under the 351(k) biosimilar pathway  Company continues to execute its analytical program and plans to request a BPD Type 2b meeting with the FDA in 2026 to discuss next steps in the development of ABP-450 as a biosimilar to BOTOX®  IRVINE, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced feedback from the U.S. Food and Drug Administration ("FDA" or the "Agency") following a successful Bios

IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

IRVINE, Calif., March 05, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced a poster presentation at the 2026 American Academy of Neurology (AAN) Annual Meeting, taking place April 18-22, 2026, in Chicago, IL. The abstract builds upon analytical data previously reported by the Company demonstrating identical primary amino acid sequence between ABP-450 and the reference product, based on 93.5%–99.3% peptide sequence coverage across BoNT/A1 and associated accessory protein

- AEON confirmed that earlier today it held its BPD Type 2a Meeting with the FDA, in line with prior guidance, and is now awaiting official meeting minutes - - Separately, AEON shareholders today voted in favor of the proposals required to complete the transactions announced in November, including the consummation of the PIPE financing and the related Daewoong note exchange - IRVINE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA), today reported on two separate posi

IRVINE, Calif., Dec. 19, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today reported the grants in December totaling 392,158 restricted stock units (RSUs) of the Company's common stock to newly hired non-executive employees of the Company. The awards were approved by the Company's Board of Directors under the Company's 2025 Inducement Incentive Plan, with a grant date of December 11, 2025 and vesting commencement dates in December 2025. The RSUs vest over four years, 25% on each annua

- AEON and Daewoong Pharmaceutical have executed definitive documentation to exchange $15 million of notes plus accrued interest into new equity, $1.5 million of new notes due 2030, and a cash-exercise warrant for 8 million shares of common stock – - Exchange remains subject to shareholder approval - IRVINE, Calif., Dec. 15, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today announced that the Company and Daewoong Pharmaceutical ("Daewoong") have entered into a definitive agreement

- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today announced the first closing of its previously announced private placement ("PIPE"). Additionally, the Company announced that the U.S. Food and Drug Administration (the "FDA") has proposed a new date of January 21, 2026 for AEON's Biosimilar Biological product Development (BPD) Type 2a meeti

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

10-K - AEON Biopharma, Inc. (0001837607) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

424B3 - AEON Biopharma, Inc. (0001837607) (Filer)

EFFECT - AEON Biopharma, Inc. (0001837607) (Filer)

S-3 - AEON Biopharma, Inc. (0001837607) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

8-K - AEON Biopharma, Inc. (0001837607) (Filer)

DEF 14A - AEON Biopharma, Inc. (0001837607) (Filer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

3 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

3 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

4 - AEON Biopharma, Inc. (0001837607) (Issuer)

H.C. Wainwright initiated coverage of AEON Biopharma with a rating of Buy and set a new price target of $18.00

IRVINE, Calif., April 03, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve full-label U.S. market entry, today announced that, on April 2, 2026, in connection with the appointment of John Bencich as Chief Financial Officer, the Company's Compensation Committee of the Board of Directors (the "Compensation Committee") approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bencich of 754,717 restricted stock units ("RSUs") under AEON's 2025 Employment Inducement Incentive Award Plan (the "Induce

IRVINE, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company advancing ABP-450 (prabotulinumtoxinA) as a biosimilar to BOTOX® (onabotulinumtoxinA) to achieve accelerated and full-label U.S. market entry, today announced the appointment of John Bencich as Chief Financial Officer. Mr. Bencich joins AEON at a pivotal stage in the Company's evolution as it prepares to execute through its next phase of critical regulatory milestones. "John's appointment represents an important step forward for AEON as we enter a period of accelerated execution," said Rob Bancroft, President and Chief Executive Officer of AEON. "His d

IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company's Compensation Committee of the Board of Directors has approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bancroft of a non-qualified stock option to purchase 59,034 shares of AEON Class A common stock under AEON's 2025 Employment Inducement Incentive Award Plan (the "I

IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Mr. Bancroft will also join AEON's Board of Directors. "We are excited to welcome Rob as the new President and Chief Executive Officer of AEON. He is an exceptional leader who brings a wealth of experience in the therapeutic toxin industry, and a strong track record of building value through the execution of well-defined s

– Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025. Mr. Forth will continue with the Company as a member of it

-- Termination of the Forward Purchase Agreements simplifies AEON's capitalization structure -- -- AEON to expand its Board of Directors with appointment of candidate selected by its strategic partner following full funding of transaction -- IRVINE, Calif., March 19, 2024 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (AMEX:AEON, AEON WS))), a clinical-stage biopharmaceutical company focused on developing a proprietary botulinum toxin complex for the treatment of multiple debilitating medical conditions, today announced it has entered definitive agreements relating to a private placement (the "Private Placement") of $15 million (the "Investment Amount") aggregate prin

SC 13G - AEON Biopharma, Inc. (0001837607) (Subject)

– Announced positive initial comparative analytical results, confirming identical amino-acid sequencing and highly similar functional characteristics to BOTOX® –  – Reported positive FDA BPD Type 2a meeting, with FDA feedback providing a clear framework for advancing the comparative analytical plan for ABP-450 biosimilar program – – Strengthened balance sheet through $6 million PIPE financing and Daewoong note exchange, reducing outstanding debt by more than 90% – – Appointed John Bencich as Chief Financial Officer, adding significant capital markets and strategic leadership experience – IRVINE, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (

– FDA Type 2a meeting scheduled for November 19, 2025, to review AEON's analytical development plan and initial data – – Positive biosimilarity data for ABP-450 confirming identical amino-acid sequencing and highly similar functional characteristics submitted to FDA ahead of scheduled Type 2a meeting – – Two complementary financing transactions announced in November 2025 - $6 million PIPE financing and a proposed Daewoong note exchange - are expected to strengthen AEON's balance sheet, reduce outstanding debt by more than 90%, accelerate the ABP-450 biosimilar program by up to six months, and extend cash runway into the second quarter of 2026 – IRVINE, Calif., Nov. 14, 2025 (GLOBE

– Multiple near-term potential milestones, including anticipated completion of primary structure analysis and select functional analyses in 3Q'25 – – Type 2a meeting with the FDA anticipated in 4Q'25– – Cash runway expected to support operations through FDA meeting and regulatory feedback – IRVINE, Calif., Aug. 12, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a biopharmaceutical company seeking an accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX® (onabotulinumtoxinA) biosimilar, announced its financial results for the second quarter ended June 30, 2025, and provided a business update. "We have ma

– Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company's President and Chief Executive Officer; Mr. Bancroft also joined AEON's Board of Directors – IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum

– ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not meet statistical significance vs. placebo because of a much higher-than-expected placebo response of 4.2 days – – Study demonstrated statistical significance on multiple secondary and exploratory endpoints, including the responder analysis of both a >50% and >75% improvement from baseline in MMD – – Totality of the data showed evidence of a dose response favoring the higher 195 units arm, and supports the decision to advance into Phase 3, anticipated in 2H 2024 – – Ongoing Phase 2 trial for the